March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.